Deals: Page 2


  • Image attribution tooltip
    AbbVie

    AbbVie keeps up dealmaking pace in neuroscience

    On the heels of its Syndesi acquisition, the company has announced an agreement with Gedeon Richter focused on researching and developing new dopamine-regulating drugs for neuropsychiatric diseases.

    By March 11, 2022
  • Image attribution tooltip
    Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.

    After slower-than-expected review, Pfizer and Arena close buyout deal

    Pfizer officially closed its $7 billion acquisition of Arena Pharmaceuticals on Friday without needing to divest any assets.

    By Updated March 11, 2022
  • Trendline

    The BioPharma Dive Outlook on 2022

    After surging into 2021, biotech crashed at the end of last year amid negative clinical trial readouts, ebbing M&A and broader investor pullback. But the year ahead figures to be busy on several fronts and a slate of important studies could deliver good news. 

    By BioPharma Dive staff
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    Novartis turns to Voyager for nervous system gene therapies

    The deal, which carries a $54 million upfront payment, could give Novartis access to as many as five of Voyager's capsids, which would be used to develop gene therapies for the central nervous system.

    By March 8, 2022
  • Bluebird's CFO resigns as cash woes raise doubts about its future

    The gene therapy developer's top financial executive, Gina Consylman, is stepping down amid concerns the company needs to raise additional cash to survive for more than a year.  

    By March 7, 2022
  • Image attribution tooltip
    Courtesy of Biocon

    Viatris sells off biosimilars business in $3.3B deal

    The sale to Biocon represents the first major step Viatris has taken to reshape itself, following a strategic review that took place throughout 2021.

    By Feb. 28, 2022
  • Image attribution tooltip
    Getty Images

    Biohaven stocks up on experimental drugs with new acquisition, licensing deal

    Separate agreements with Channel Biosciences and Bristol Myers Squibb give Biohaven access to experimental treatments for spinal muscular atrophy and for epilepsy.

    By Feb. 25, 2022
  • Image attribution tooltip

    James Thew/stock.adobe.com

    Sponsored by TrialCard

    Copay accumulators, maximizers and the CMS best price rule: What you need to know now

    Copay accumulators, maximizers and best price concerns dominated the copay assistance landscape in 2021. Here is an update on the most prominent developments in this area over the last six months.

    By Jason Zemcik, Vice President, Patient Affordability, TrialCard • Feb. 22, 2022
  • Image attribution tooltip
    Getty Images

    Pressed by Wall Street, pharma executives signal openness to M&A

    Despite tumbling biotech valuations, however, several said they still prefer smaller-sized "bolt-on" deals to larger, potentially more disruptive, transactions.

    By Feb. 7, 2022
  • Image attribution tooltip
    Courtesy of Intellia Therapeutics

    Intellia, expanding in gene editing, buys startup Rewrite for $45M

    Founded by University of California, Berkeley scientists, Rewrite is studying ways to expand the reach of gene editing beyond limitations of current technologies, including Intellia's. 

    By Feb. 3, 2022
  • Image attribution tooltip
    Getty Images

    Biogen, facing pressure on all sides, sells stake in biosimilars business

    The biotech will sell the roughly 50% stake it holds in a biosimilars joint venture to Samsung Biologics for as much as $2.3 billion — cash that analysts expect the drugmaker to invest in M&A.

    By , Jan. 28, 2022
  • Image attribution tooltip
    Mario Tama via Getty Images

    J&J 'constantly looking' at biotech M&A, but focused on small, mid-sized deals

    Despite sliding stock prices, biotechs aren't "on sale," J&J CFO Joe Wolk said Tuesday. "It's really hard to say whether there's been a capitulation, or a recognition, that values have come down."

    By Jan. 25, 2022
  • Image attribution tooltip
    Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.

    Antitrust regulators aim to revamp merger guidelines, signaling threat to health sector deals

    The news sparked headlines about an attempt by regulators to target big tech, but it could have serious implications for healthcare, too. 

    By Samantha Liss • Jan. 19, 2022
  • Image attribution tooltip
    Getty Images

    UCB to buy Zogenix for nearly $2B in 'first step' for M&A in 2022

    The acquisition will give the Belgian pharma access to an epilepsy drug that won U.S. approval in June 2020 but that Zogenix has struggled to sell. 

    By Jan. 19, 2022
  • Image attribution tooltip
    Brian Tucker / BioPharma Dive

    5 questions facing biotech M&A in 2022

    Analysts expect that deal engines are ready to start firing again following the recent quiet period. Still, uncertainty remains about how biopharma acquisitions could play out in the coming months.

    By Jan. 12, 2022
  • Image attribution tooltip
    Danielle Ternes / BioPharma Dive

    JPM22: M&A anxiety, Roche's comeback plan and Vir's omicron moment

    Pharma executives fielded many questions about their dealmaking intentions on the conference's second day, while Roche outlined its plan to compete against Merck and Bristol Myers in cancer immunotherapy.

    By , Jan. 11, 2022
  • Image attribution tooltip
    Dan Kitwood via Getty Images
    CRISPR gene editing

    Pfizer expands into gene editing with Beam research deal

    Pfizer's work with mRNA vaccines led it to explore other applications of the technology, resulting in a multiyear partnership with the high-profile biotech Beam Therapeutics on gene editing treatments for rare diseases.

    By Jan. 10, 2022
  • Lilly pours more money into genetic treatments for neurological diseases

    For $50 million, Lilly has secured rights to a technology that's meant to transport nucleic acid therapies in a way that's more targeted and better tolerated than other methods.

    By Jan. 6, 2022
  • Image attribution tooltip
    Permission granted by Biogen

    Biogen brings in a successor to Spinraza

    The company spent $60 million to secure global rights to an experimental drug developed by Ionis Pharmaceuticals to treat spinal muscular atrophy.

    By Jan. 4, 2022
  • Image attribution tooltip
    Novartis

    Novartis ups investment in gene therapy for the eye with $800M buyout

    The deal for Gyroscope Therapeutics, worth up to $1.5 billion, gives the Swiss pharma access to a treatment for a type of age-related blindness as well as new means of delivering drugs into the eye.

    By Dec. 22, 2021
  • Image attribution tooltip
    Courtesy of Sanofi

    Sanofi to buy cancer immunotherapy biotech for $1B

    The French drugmaker is interested in Amunix Pharmaceuticals' technology, which could allow for more precise delivery of biologic drugs into cancerous tissue.

    By Dec. 21, 2021
  • Image attribution tooltip
    Permission granted by Bristol-Myers Squibb

    Bristol Myers returns to Immatics for a dual-targeting cancer drug

    The pharma has expanded an alliance with a German biotech by paying $150 million for a drug candidate that executives hope can have "cell therapy-like efficacy" for solid tumors. 

    By Dec. 14, 2021
  • Image attribution tooltip
    Dan Kitwood via Getty Images

    Arena, completing its turnaround, sells to Pfizer for nearly $7 billion

    Pfizer will pay $100 per share to acquire Arena and the portfolio of inflammatory disease medicines it developed in the wake of a disappointing drug launch.

    By Updated Dec. 13, 2021
  • Sobi buyout breaks down

    Three months after proposing a roughly $8 billion acquisition of Sobi, the investment firms Advent International and GIC have withdrawn their offer.

    By Dec. 3, 2021
  • Image attribution tooltip
    Novartis

    Novartis pays $150M for access to UCB's Parkinson's drug

    UCB's experimental pill is one of the most advanced projects that's aimed at blocking accumulation of an abnormal protein in patients' brains.

    By Dec. 2, 2021
  • Image attribution tooltip
    Warren Little via Getty Images

    GSK sets sights on brain diseases through Oxford partnership

    Equipped with $40 million in funding, a new institute from GSK and Oxford will initially focus on developing treatments for Alzheimer's, Parkinson's, ALS and other neurological conditions.

    By Dec. 2, 2021